Safety and Immunogenicity of a Live Attenuated RSV Vaccine in Healthy RSV-Seronegative Children 5 to 24 Months of Age

Despite substantial morbidity associated with respiratory syncytial virus (RSV) infection, there is no licensed vaccine. MEDI-559 is a live attenuated intranasal vaccine candidate being developed for prevention of lower respiratory illness due to RSV in young children. This randomized, placebo-contr...

Descripción completa

Detalles Bibliográficos
Autores principales: Malkin, Elissa, Yogev, Ram, Abughali, Nazha, Sliman, Joseph, Wang, C. Kathy, Zuo, Fengrong, Yang, Chin-Fen, Eickhoff, Mark, Esser, Mark T., Tang, Roderick S., Dubovsky, Filip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3812203/
https://www.ncbi.nlm.nih.gov/pubmed/24204744
http://dx.doi.org/10.1371/journal.pone.0077104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3812203/
https://www.ncbi.nlm.nih.gov/pubmed/24204744
http://dx.doi.org/10.1371/journal.pone.0077104

Ejemplares similares